人类免疫缺陷病毒阳性患者经高效抗逆转录病毒治疗血液学指标变化

Hematological parameters changes in HIV positive patients taking active antiretroviral treatment

  • 摘要: 目的 探讨人类免疫缺陷病毒(human immunodeficiency virus,HIV)阳性患者高效抗逆转录病毒治疗血液学指标变化,与临床疾病的关系。 方法 我院2013年11月- 2014年12月收治的100例HIV阳性患者,随机分为两组,55例高效抗逆转录病毒(highly active antiretroviral therapy,HAART)治疗组(On HAART)和45例未进行该治疗的HIV患者为对照组(HAART naïve),分别采用流式细胞术(flow cytometry,FCM)检测外周血T淋巴细胞亚群百分比、细胞计数,采用核酸荧光染料和FCM检测白细胞计数(white blood cell,WBC)、红细胞计数(red blood cell,RBC)、血色素(hemoglobin,Hgb)、红细胞压积(hematocrit,HCT)、平均RBC体积(mean corpuscular volume,MCV)、平均RBC血红蛋白(mean corpuscular hemoglobin,MCH)、平均血红蛋白浓度(mean corpuscular hemoglobin concentration,MCHC)、RBC分布宽度(red blood cell volume distribution width,RDW)、血小板计数(platelets,PLT)、血小板容积(plateletcrit,PCT)、血小板分布宽度(platelet distribution width,PDW)和血小板平均体积(mean platelet volume,MPV)等,采用免疫比浊法检测凝血酶原时间(prothrombin time,PT)、凝血酶原活动度(prothrombin activity,PTA)水平,并采用荧光定量PCR法检测患者HIV病毒载量(HIVRNA)。观察HIV阳性患者经高效抗逆转录病毒治疗血液学指标变化特点。 结果 治疗组与对照组在治疗前血液学指标差异无统计学意义(P> 0.05)。治疗后治疗组Hgb、MCV、MCH、MCHC、CD4和CD8+ T淋巴细胞数(14.2 g/dl、90.5 fl、35.3 pg、336.1 g/L、395.4 /μl、795.4 /μl)显著高于对照组的(12.7 g/dl、87.5 fl、28.4 pg、322.6 g/L、300.7 /μl、679.7 /μl)(P< 0.05),WBC和RBC水平(4.9×103/μl和4.0×106/μl)显著低于对照组(5.8×103/μl和4.7×106/μl)(P< 0.05)。 结论 高效抗病毒治疗可降低HIV患者贫血和血小板降低发生率,但易发生白细胞、粒细胞和淋巴细胞减少症。临床医生应根据患者血液学指标变化考虑药物组合、疗程和禁忌。

     

    Abstract: Objective Toinvestigate hematological parameters changes in human immunodeficiency virus (HIV) positive patients taking active antiretroviral treatment and explore its clinical significance. Methods One hundredHIV positive patients admittedtoour hospital fromNovember 2013 toDecember 2014 were enrolledin this study, and they were dividedintotwogroups: highly active antiretroviral therapy (HAART) group(n=55) and HARRT na ve group(n=45). The levels of peripheral bloodCD3+, CD3+ CD4+ and CD3+CD8+ T-lymphocytes were detectedby flowcytometry. WBC, RBC, Hgb, HCT, MCV, MCH, MCHC, RDW, PLT, and MPV were determinedby nucleic acidfluorescent dye methodand flowcytometry. PT and PTA levels were detectedby immunoturbidimetry. HIVRNA were determinedby fluorescent quantitation PCR methods, and the characteristics of hematological parameters in HIV positive patients taking active antiretroviral treatment were observed. Results There was nostatistically significant difference between observation groupand control groupin hematology indexes (P> 0.05). Prevalence of anemia, leucopenia, thrombocytopenia, neutropenia and lymphopenia were 12.0%, 36.0%, 4.0%, 28.0% and 5.3% in patients taking HAART and 30.7%, 16.9%, 9.2%, 13.8% and 4.6% in HAART na ve patients respectively. There were significant differences in total WBC, RBC, Hgb, MCV, MCH, MCHC, MPV and CD4 counts between patients taking HAART and HAART na ve patients (P< 0.05). Conclusion HAART can reduce the incidence of anemia and thrombocytopenia in patients with HIV, but it is prone tohave leucopenia, neutropenia and lymphopenia. Clinicians needtotake consideration about drug combination, course of treatment and treatment tabooin HIV positive patients according tochanges of hematological indexes.

     

/

返回文章
返回